Methionine enkephalin

Drug Profile

Methionine enkephalin

Alternative Names: INNO-105; IRT-101; IRT-102; MENK; Met-enkephalin; OGF; Opioid growth factor

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Cytocom; Hubei Qianjiang Pharmaceutical; Immune Therapeutics
  • Class Antivirals; Enkephalins; Essential amino acids; Opioid peptides; Small molecules
  • Mechanism of Action Immunomodulators; Immunostimulants; Opioid growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; HIV infections; Ovarian cancer; Pancreatic cancer
  • Clinical Phase Unknown Solid tumours
  • Discontinued Influenza virus infections

Most Recent Events

  • 13 Aug 2014 TNI BioTech and Hubei Qianjiang Pharmaceutical expand existing agreement for co-development of methionine enkephalin in USA and China
  • 26 Mar 2014 Phase-II development in Pancreatic cancer is ongoing in USA
  • 26 Mar 2014 TNI BioTech and Hubei Qianjiang Pharmaceutical expand existing agreement for co-development of methionine enkephalin in USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top